Prescription Pricing for the People Act of 2025
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in senate (Feb 11, 2025)
Prescription Pricing for the People Act of 2025
This bill requires the Federal Trade Commission (FTC) to report about anticompetitive practices and other trends within the pharmaceutical supply chain that may impact the cost of prescription drugs.
The report must address whether pharmacy benefit managers (PBMs) (1) reimburse pharmacies owned by the PBM at a higher price than other pharmacies, and (2) implement formulary designs to increase the market share of higher-cost prescription drugs or depress the market share of lower-cost prescription drugs.
The FTC also must provide recommendations to increase transparency in the supply chain, prevent anticompetitive practices, and ensure that consumers benefit from cost savings or efficiencies that result from mergers and consolidations.
Additionally, the FTC must report the number and nature of complaints the FTC receives relating to an allegation of anticompetitive conduct by a manufacturer of a sole-source drug.
What just happenedApr 10, 2025
Placed on Senate Legislative Calendar under General Orders. Calendar No. 42.
Who’s behind it
- Reported to SenateApr 10, 2025
- Introduced in SenateFeb 11, 2025
- Apr 10, 2025Calendars
Placed on Senate Legislative Calendar under General Orders. Calendar No. 42.
- Apr 10, 2025Committee
Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.
Judiciary Committee - Apr 10, 2025Committee14000
Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.
Judiciary Committee - Apr 3, 2025Committee
Committee on the Judiciary. Ordered to be reported without amendment favorably.
Judiciary Committee - Feb 11, 2025IntroReferral
Read twice and referred to the Committee on the Judiciary.
Judiciary Committee - Feb 11, 2025IntroReferral10000
Introduced in Senate